This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cannabis ETFs Soar Double-Digits on Friday: Here's Why
by Sanghamitra Saha
Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.
Philip Morris Hits Record High on Q3 Earnings Beat: ETFs in Focus
by Yashwardhan Jain
Look at ETFs with exposure to Philip Morris, as the tobacco giant beats earnings estimates and surges to a record high.
Philip Morris Beats Estimates in Q1 Earnings: ETFs in Focus
by Yashwardhan Jain
Philip Morris beat expectations for both revenues and earnings, driven by robust pricing and increased product volumes.
Philip Morris' Q3 Earnings Beat Puts ETFs in Focus
by Yashwardhan Jain
Look into ETFs with an exposure in PM, as the tobacco company reports robust Q3 earnings.
5 ETFs to Make the Most of Philip Morris's Q2 Earnings Beat
by Yashwardhan Jain
Philip Morris beat both earnings and revenue estimates in the second quarter. Look into some ETFs to capitalize.
Roundhill's Cannabis ETF (WEED) Launch Seems Timely
by Sanghamitra Saha
Roundhill Investments recently announced the launch of its own cannabis ETF, namely Roundhill Cannabis ETF (WEED).
Cannabis ETFs to Surge on Banking Bill Approval in House
by Sanghamitra Saha
On Apr 19, the U.S. House of Representatives okayed legislation that would allow banks to provide services to cannabis companies in states where it is legal.
Cannabis On a Roll: Guide to ETF Investing
by Sanghamitra Saha
Shares of cannabis-related stocks and ETFs continue to be in good shape after a solid run last year.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.